BioMed Realty joins BioIndustry Association to strengthen commitment to UK life sciences

It represents a massive boost for the sector and signals significant co-operation between the company and Europe’s most significant biotech cluster.

“Joining BIA is an important step in our ongoing commitment to supporting the UK’s life sciences industry,” said Orestis Tzortzoglou, Vice President and Head of UK Market at BioMed Realty.

“Not only are we furthering our mission to collaborate with leaders in the life science and technology sectors, but also we will further our voice and industry presence to advocate for the policies that truly foster innovation while we provide the physical infrastructure needed for groundbreaking research and development.”

BioMed Realty’s membership also offers opportunities to build relationships with leading biotech firms, investors, and research organisations. BIA’s members include a number of high-profile tenants within BioMed Realty’s portfolio, such as Bicycle Therapeutics, Cancer Research UK, Illumina and LoQus23 Therapeutics.

Steve Bates, CEO of BIA, said: “I am delighted that BioMed Realty are joining the BIA community. They bring global reach and deep understanding of what it takes to run successful facilities for life science companies.

“Adding BioMed’s expert voice to our community will enable connections for Members to grow faster, as well as inform our engagement with government – especially around the Oxford-Cambridge Arc infrastructure development.”

As a BIA member, BioMed Realty will collaborate with a 600-strong network of industry leaders, academic institutions, and policymakers to help shape the future of the life sciences sector.

The company first entered the Cambridge, UK market in 2012 and is playing a key role in helping the government achieve its ambitions of transforming the country into a ‘science superpower’ by delivering infrastructure that accelerates tenants’ capacity for innovation.

BioMed Realty, a Blackstone portfolio company, owns and operates nearly one million square feet of space in Cambridge, including Granta Park and Babraham Research Campus. It is a leading provider of real estate solutions to the life science and technology industries. BioMed owns and operates high quality life science real estate comprising – as of December 31, 2024 –16.3 million square feet concentrated in leading innovation markets throughout the US and UK, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder and Cambridge, UK.

BioMed also maintains a premier in-process development platform with 2.5 million square feet of Class A properties in active construction to meet the growing demand of the life science and technology industries.